Managing atypical hemolytic uremic syndrome: chapter 2 | Zendy

Carla Nester | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Managing atypical hemolytic uremic syndrome: chapter 2

Author(s) -

Carla Nester

Publication year - 2015

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2015.60

Subject(s) - atypical hemolytic uremic syndrome , eculizumab , medicine , intensive care medicine , kidney disease , renal function , thrombotic microangiopathy , pediatrics , disease , immunology , antibody , complement system

Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment. This report adds a layer of comfort to our care of patients with this rare disease; however, it is unlikely to be the final chapter in the treatment of aHUS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research